Analysts/Institutional Investor Meet/Con. Call Updates

AI summary - Q1 FY27 consolidated revenue grew 24% y-y to INR 1,588 Cr; EBITDA up 24% to INR 428 Cr; PAT rose 19% to INR 219 Cr - Chemical segment revenue increased 23% y-y to INR 1,574 Cr; EBITDA grew 29% to INR 458 Cr; PAT up 33% to INR 261 Cr - Fluoropolymer revenue grew 15% y-y driven by higher-value grades and volume growth - Fluorochemical revenue surged 52% y-y led by R32 refrigerant sales; R32 capacity expansion expected Q2 FY27 - Battery materials progressing; significant revenue ramp-up expected from Q4 FY27 and FY28 - ROCE improved to 16.6%, ROE to 15.18%; working capital days reduced to 149 - Capex plan: INR 2,300 Cr for EV and INR 800 Cr for chemical business in FY27 - Management confident on 17-20% annual fluoropolymer growth and strong fluorochemical contribution - New fluoropolymer approvals expected by FY27 end enabling faster capacity ramp-up - Full utilization expected for incremental R32 capacity in calendar year 2027